Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Notification of Interim Results

30 Oct 2014 07:00

RNS Number : 6549V
ReNeuron Group plc
30 October 2014
Ā 

Ā 

30 October 2014

AIM: RENE

Ā 

ReNeuron Group plc

("ReNeuron" or "the Company")

Ā 

Notification of Interim Results

Ā 

ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its interim results for the six months ended 30 September 2014 on Monday 17 November 2014.

Ā 

A meeting for analysts will be held at 10.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

Ā 

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results:Ā http://vm.buchanan.uk.com/2014/reneuron171114/registration.htm.

Ā 

A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com.

Ā 

Ā 

Enquiries:

Ā 

ReNeuron

Olav HellebĆø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

Ā 

+44 (0) 1483 302560

Buchanan

Mark Court, Sophie Cowles

Ā 

+44 (0) 20 7466 5000

Cenkos Securities

Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Andy Roberts (Sales)

Ā 

+44 (0) 20 7397 8900

Ā 

About ReNeuron

Ā 

ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

Ā 

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development.

Ā 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Ā 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
NOREANENAFXLFFF
Date   Source Headline
2nd Sep 20247:00 amRNSCancellation - ReNeuron Group Plc
30th Aug 20247:00 amRNSCorporate update and AIM cancellation
2nd Aug 202412:25 pmRNSCorporate Update
26th Jun 20243:33 pmRNSChange of Registered Address
5th Jun 20243:36 pmRNSCreditor’s decision on Administrators' Proposals
17th May 202412:45 pmRNSPublication of Joint Administrators' Proposals
8th May 20247:00 amRNSUpdate on Administration Process
17th Apr 202411:30 amRNSDirectorate Change
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.